BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global ...

The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...

BD said all configurations feature high-throughput automation and software designed for large dataset management and ...

Single-cell sequencing provides unprecedented detail into cell-to-cell variability, uncovering key biological mechanisms in ...

Cytek Biosciences has recurring revenue growth, improving margins, and ample cash that should continue compounding shareholder value over time. See why CTKB is a Buy.

In this edition of the biotech bi-weekly, we highlight the latest exciting product launches, partnerships and company events.

The Francis Crick Institute’s flow cytometry core has shown at ELRIG 2025 how a heterogeneous fleet of spectral, mass and ...

A central challenge in relapsed/refractory follicular lymphoma is determining a treatment sequence that maximizes current ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Study links anxiety to 74% fewer natural killer cells—immune defenders against cancer and infections. Insomnia intensifies ...

The IDEXX Cancer Dx is a new blood-based screening/diagnostic panel aimed at detecting canine lymphoma from serum or whole ...

Survival rarely comes easy when pancreatic ductal adenocarcinoma strikes. Most people learn of it only after it has spread, ...